GT201300306A - Anticuerpos anti-angptl3 y usos de los mismos - Google Patents
Anticuerpos anti-angptl3 y usos de los mismosInfo
- Publication number
- GT201300306A GT201300306A GT201300306A GT201300306A GT201300306A GT 201300306 A GT201300306 A GT 201300306A GT 201300306 A GT201300306 A GT 201300306A GT 201300306 A GT201300306 A GT 201300306A GT 201300306 A GT201300306 A GT 201300306A
- Authority
- GT
- Guatemala
- Prior art keywords
- same
- angptl3 antibodies
- antibodies
- methods
- human antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS HUMANOS Y FRAGMENTOS DE FIJACIÓN DE ANTÍGENO DE ANTICUERPOS HUMANOS QUE SE FIJAN ESPECÍFICAMENTE A LA PROTEÍNA 3 DE TIPO ANGIOPOYETINA HUMANA (HANGPTL3), Y MÉTODOS TERAPÉUTICOS DE UTILIZACIÓN DE DICHOS ANTICUERPOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498518P | 2011-06-17 | 2011-06-17 | |
| US201161578309P | 2011-12-21 | 2011-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201300306A true GT201300306A (es) | 2015-03-09 |
Family
ID=46298728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201300306A GT201300306A (es) | 2011-06-17 | 2013-12-11 | Anticuerpos anti-angptl3 y usos de los mismos |
Country Status (42)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3412B1 (ar) * | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2017011929A1 (zh) * | 2015-07-17 | 2017-01-26 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX2018009680A (es) | 2016-02-17 | 2018-09-10 | Regeneron Pharma | Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3. |
| EA201891979A1 (ru) * | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| RS62769B1 (sr) * | 2016-04-08 | 2022-01-31 | Regeneron Pharma | Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
| MX2018012741A (es) * | 2016-04-28 | 2019-05-16 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| EA201991203A1 (ru) | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| US20200393470A1 (en) | 2017-12-18 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的***和方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| BR112020013426A2 (pt) | 2018-02-28 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células |
| CN111868085A (zh) | 2018-03-19 | 2020-10-30 | 瑞泽恩制药公司 | 微芯片毛细管电泳测定法及试剂 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN112218877A (zh) | 2018-08-27 | 2021-01-12 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| CN112601963A (zh) | 2018-08-30 | 2021-04-02 | 瑞泽恩制药公司 | 用于表征蛋白质复合物的方法 |
| JP2022513626A (ja) * | 2018-11-26 | 2022-02-09 | ノバルティス アーゲー | Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CA3116732A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
| US20220144961A1 (en) * | 2019-03-11 | 2022-05-12 | Xyence Therapeutics, Inc. | Cd27-binding antibodies and uses thereof |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| US20200369760A1 (en) * | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| WO2021001804A1 (en) * | 2019-07-04 | 2021-01-07 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| MX2022003438A (es) | 2019-09-24 | 2022-04-19 | Regeneron Pharma | Sistemas y metodos para uso y regeneracion de cromatografia. |
| KR20220104797A (ko) | 2019-11-25 | 2022-07-26 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 에멀전을 이용한 지속 방출 제형 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| KR102544013B1 (ko) | 2020-01-21 | 2023-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
| AU2021209746A1 (en) * | 2020-01-22 | 2022-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-ANGPTL3 antibody and use thereof |
| EP4204578A1 (en) | 2020-08-31 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| AU2022230987A1 (en) | 2021-03-03 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| WO2022205021A1 (zh) * | 2021-03-30 | 2022-10-06 | 复旦大学附属儿科医院 | 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途 |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| WO2023001228A1 (zh) * | 2021-07-21 | 2023-01-26 | 江苏恒瑞医药股份有限公司 | 一种抗angptl3抗体或其抗原结合片段的药物组合物及其用途 |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
| CN116284377A (zh) * | 2021-12-21 | 2023-06-23 | 复旦大学 | 抗人血管生成素3纳米抗体及其应用 |
| WO2023122656A1 (en) * | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
| CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN1273112C (zh) | 2001-02-22 | 2006-09-06 | 斯凯伊药品加拿大公司 | 具有减少进食－禁食作用的贝特－它汀组合 |
| WO2003044172A2 (en) * | 2001-11-16 | 2003-05-30 | Genentech, Inc. | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| EP2322202A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| WO2006098887A2 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| CA2630839C (en) | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| CN101522716B (zh) * | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| PT2121751T (pt) * | 2006-12-08 | 2017-04-18 | Lexicon Pharmaceuticals Inc | Anticorpos monoclonais contra angptl3 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| BR112012000914B8 (pt) | 2009-07-14 | 2021-05-25 | Irm Llc | uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular |
| AU2011203986C1 (en) | 2010-01-08 | 2015-03-05 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| MX345095B (es) * | 2011-06-21 | 2017-01-17 | Alnylam Pharmaceuticals Inc | Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso. |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014369900B2 (en) | 2013-12-24 | 2021-05-20 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| EP3845547A1 (en) | 2014-05-01 | 2021-07-07 | Ionis Pharmaceuticals, Inc. | Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression |
| PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX2018009680A (es) | 2016-02-17 | 2018-09-10 | Regeneron Pharma | Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3. |
| EA201891979A1 (ru) | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| RS62769B1 (sr) | 2016-04-08 | 2022-01-31 | Regeneron Pharma | Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
| MX2018012741A (es) | 2016-04-28 | 2019-05-16 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. |
-
2012
- 2012-06-13 JO JOP/2012/0155A patent/JO3412B1/ar active
- 2012-06-13 AR ARP120102099A patent/AR087329A1/es active IP Right Grant
- 2012-06-14 SG SG2013087432A patent/SG195165A1/en unknown
- 2012-06-14 MX MX2015017575A patent/MX361859B/es unknown
- 2012-06-14 PE PE2013002804A patent/PE20141166A1/es active IP Right Grant
- 2012-06-14 AU AU2012271663A patent/AU2012271663B2/en active Active
- 2012-06-14 WO PCT/US2012/042338 patent/WO2012174178A1/en active Application Filing
- 2012-06-14 PT PT12727767T patent/PT2721065T/pt unknown
- 2012-06-14 KR KR1020147000902A patent/KR102031007B1/ko active IP Right Grant
- 2012-06-14 LT LTEP12727767.1T patent/LT2721065T/lt unknown
- 2012-06-14 RS RS20181508A patent/RS58310B1/sr unknown
- 2012-06-14 PL PL12727767T patent/PL2721065T3/pl unknown
- 2012-06-14 TR TR2018/16591T patent/TR201816591T4/tr unknown
- 2012-06-14 US US13/517,662 patent/US9018356B2/en active Active
- 2012-06-14 UA UAA201314628A patent/UA114891C2/uk unknown
- 2012-06-14 JP JP2014515976A patent/JP6400471B2/ja active Active
- 2012-06-14 RU RU2013155906A patent/RU2620064C2/ru active
- 2012-06-14 MX MX2013014345A patent/MX337644B/es active IP Right Grant
- 2012-06-14 CA CA2838867A patent/CA2838867C/en active Active
- 2012-06-14 SI SI201231444T patent/SI2721065T1/sl unknown
- 2012-06-14 EP EP18185031.4A patent/EP3418301A1/en not_active Withdrawn
- 2012-06-14 ES ES12727767T patent/ES2699499T3/es active Active
- 2012-06-14 CN CN201280038908.0A patent/CN103732624B/zh active Active
- 2012-06-14 EP EP12727767.1A patent/EP2721065B1/en active Active
- 2012-06-14 MY MYPI2013004223A patent/MY160516A/en unknown
- 2012-06-14 DK DK12727767.1T patent/DK2721065T3/en active
- 2012-06-15 TW TW106123582A patent/TW201815822A/zh unknown
- 2012-06-15 UY UY0001034137A patent/UY34137A/es not_active Application Discontinuation
- 2012-06-15 UY UY0001039340A patent/UY39340A/es not_active Application Discontinuation
- 2012-06-15 TW TW107135714A patent/TW201920261A/zh unknown
- 2012-06-15 TW TW101121453A patent/TWI644922B/zh active
-
2013
- 2013-11-25 IL IL229612A patent/IL229612B/en active IP Right Grant
- 2013-11-26 CR CR20130621A patent/CR20130621A/es unknown
- 2013-11-26 ZA ZA2013/08879A patent/ZA201308879B/en unknown
- 2013-12-06 NI NI201300136A patent/NI201300136A/es unknown
- 2013-12-11 DO DO2013000299A patent/DOP2013000299A/es unknown
- 2013-12-11 GT GT201300306A patent/GT201300306A/es unknown
- 2013-12-11 CL CL2013003552A patent/CL2013003552A1/es unknown
- 2013-12-13 CO CO13292222A patent/CO6821892A2/es unknown
- 2013-12-16 EC ECSP13013085 patent/ECSP13013085A/es unknown
- 2013-12-17 MA MA36579A patent/MA35190B1/fr unknown
-
2015
- 2015-03-24 US US14/667,121 patent/US9951127B2/en active Active
-
2018
- 2018-04-20 US US15/958,996 patent/US10358487B2/en active Active
- 2018-05-16 IL IL259436A patent/IL259436A/en active IP Right Grant
- 2018-07-06 JP JP2018128768A patent/JP2018166516A/ja active Pending
- 2018-12-11 CY CY181101324T patent/CY1120996T1/el unknown
- 2018-12-12 HR HRP20182098TT patent/HRP20182098T1/hr unknown
-
2019
- 2019-06-07 US US16/435,032 patent/US20190315851A1/en not_active Abandoned
-
2021
- 2021-09-01 NL NL301122C patent/NL301122I2/nl unknown
- 2021-09-06 LT LTPA2021009C patent/LTC2721065I2/lt unknown
- 2021-09-06 HU HUS2100034C patent/HUS2100034I1/hu unknown
- 2021-09-09 FI FIC20210028C patent/FIC20210028I1/fi unknown
- 2021-09-15 NO NO2021037C patent/NO2021037I1/no unknown
-
2022
- 2022-01-27 US US17/586,662 patent/US20220153825A1/en not_active Abandoned
- 2022-09-08 US US17/930,704 patent/US20220403016A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300306A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
| CY1123435T1 (el) | Anti-pd-l1 αντισωματα και χρησεις αυτων | |
| BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
| CR20150329A (es) | Inmunoglobulinas heterodiméricas | |
| CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
| CL2015001507A1 (es) | Proteínas de unión al antígeno bcma | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
| EA201391597A1 (ru) | Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки | |
| GT201700131A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| CO7081144A2 (es) | Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos | |
| GT201300186A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
| UY34343A (es) | Proteinas de unión al antígeno cd27l | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| CO7010784A2 (es) | Moléculas que son anticuerpos con especificidad por ox40 humano | |
| UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
| EA201590731A1 (ru) | Антитела к гемагглютинину и способы применения | |
| BR112013027224A2 (pt) | proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados | |
| EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ |